Clinical Trial Search

Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants

Primary: Overall Objective Response — 1; 21; 26 participants

Primary: Local Disease Control Assessed by Physical Examination — 0 Participants

Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 1; 1; 0; 1 Participants

Primary: Best Overall Response Rates by Week 16 (ITT) — 0; 0; 0; 0 percentage of participants — p=0.1

Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants

Primary: Number of Participants That Experienced Dose Limiting Toxicities (DLTs) Using CTCAE, Version 4.0 — 0 participants

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Objective Response Rate — 6; 5; 14 participants

Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin

Primary: Percentage of Participants in Objective Response at 6 Months — 0.0; 0.0; 0.0; 6.7 percentage of participants

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…

Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Number of Patients With Abdominal Recurrence or Death — 72; 73; 61; 60 Participants — p=0.955

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Tumor Best Response Rate — 0 Participants

Primary: Progression-free Survival Rate, Defined as CR + PR + SD, as Assessed by RECIST Criteria — 4; 57; 98 participants

Primary: Number of Participants With Unacceptable Toxicity — 0; 0; 0; 0 participants

Primary: Rate of Late Radiation Morbidity (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis, or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by EORTC/RTOG…

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Overall Response Rate (ORR) — 9; 3; 6 participants

Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants